Fosun Pharma Plans 60% Stake In Class III Hospital For RMB 693 Million
This article was originally published in PharmAsia News
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. announced plans to acquire a 60% stake in Chancheng District Central Hospital of Foshan City for RMB 693 million ($113 million).
You may also be interested in...
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.